reports
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Exp...
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences — AMD Ryzen™ AI 300 Series Processors Unlock Transformational AI Experiences for Windows Copilot+ PCs — — AMD Ryzen™ 9000 Series Processors Set New Standards in Efficiency, Performance, and Content Creation — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- Today, during Computex 2024, (NASDAQ: AMD) announced a groundbreaking series of next-generation architecture and products aimed at ushering in a new era of AI experiences. AMD is introducing new AMD Ryzen™ AI 300 Series processors with the world’s most p...
AMD Accelerates Pace of Data Center AI Innovation and Leadership with ...
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap — Updated AMD Instinct accelerator roadmap brings annual cadence of leadership AI performance and memory capabilities — — New AMD Instinct MI325X accelerator expected to be available in Q4 2024 with up to 288GB of HBM3E memory; new AMD Instinct MI350 series accelerators based on AMD CDNA 4 architecture expected to be available in 2025 with 35x generational increase in AI inference performance — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- At Computex 2024, (NASDAQ: AMD) show...
AMD Extends AI and High-Performance Leadership in Data Center and PCs ...
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024 — Expanded AMD Instinct accelerator roadmap brings annual cadence of leadership AI accelerators; next generation AMD EPYC processors to extend data center CPU leadership — — New AMD Ryzen AI 300 Series laptop and AMD Ryzen 9000 Series desktop processors deliver leading performance for Copilot+ PCs, gaming, content creation and productivity — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- Today at the Computex 2024 opening keynote, (NASDAQ: AMD) deta...
- Alicia Garcia Herrero
- Jianwei Xu
Financial outflow-driven RMB will not help correct China’s external im...
Since the trade war, and in particular after the imposition of US tariffs on China’s electric vehicles and solar panels, market observers have been speculating whether the PBoC will allow further depreciation of the yuan to counteract the impact. The latest RMB movement seems to indicate that this is the case, but the actual situation is more complex than it appears at first glance.The experience of recent years show that China’s exchange rate has been largely driven by capital flows rather than...
- Jo Yee Ng
- Shirley Wang Xueyi
- Stella Guo Yuting
Macau Gaming: May 24 GGR up 9% mom.
May 24 GGR met our and the street’s estimates. We expect the sector’s GGR to improve in 2Q24, on the back of supportive visa policies and operators’ attractive packages to drive premium-mass customers. Operating expenses of gaming operators should have largely stabilised in 2Q24 after a heated competition in 1Q24. Our top pick is Galaxy as it has reversed its market share loss 2Q24 to date and share gains could flow through EBITDA with a flattish opex qoq. Maintain MARKET WEIGHT.
- Ceilica Su Rui
- Tham Mun Hon
China Economics: PMI -- May 24 manufacturing PMI back to contraction.
Manufacturing PMI fell to 49.5% after two months of expansion, dragged by slower production and weaker new orders, which came in at 50.8% (-2.1ppt mom) and 49.6% (-1.5ppt mom) respectively. Although the non-manufacturing PMI (51.1%) remained in expansion, most of its key subcategories were still below the 50% mark. May’s weak reading aligns with the slowdown in the global manufacturing PMI; hence, it is crucial that the July Politburo meeting delivers further growth-supportive measures.
- Ceilica Su Rui
- Jo Yee Ng
- Shirley Wang Xueyi
- Stella Guo Yuting
- Tham Mun Hon
Greater China Daily: Monday, June 3, 2024
KEY HIGHLIGHTS Economics PMI Manufacturing PMI fell to 49.5% after two months of expansion, dragged by slower production and weaker new orders, which came in at 50.8% (-2.1ppt mom) and 49.6% (-1.5ppt mom) respectively. Although the non-manufacturing PMI (51.1%) remained in expansion, most of its key subcategories were still below the 50% mark. May’s weak reading aligns with the slowdown in the global manufacturing PMI; hence, it is crucial that the July Politburo meeting delivers further growt...
- Jonathan Koh
- Singapore Research Team
Singapore Daily - Monday, June 03, 2024
KEY HIGHLIGHTS Strategy Alpha Picks: Strong Performance. Add CENT, CVL, SIAEC And Remove CD, MPACT, YZJ, RSTON: Our Alpha Picks portfolio rose 3.8% mom in May 24, outperforming the STI by 2.5ppt Update Mapletree Pan Asia Commercial Trust (MPACT SP/BUY/S$1.22/Target: S$1.90): Deleveraging to add strategic flexibility. TRADERS’ CORNER Hongkong Land Holdings (HKL SP): Trading BUY Top Glove Corp (TOPG SP): Trading BUY
- Leonard Law
Lucror Analytics - Morning Views Asia
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar. To request full and unrestricted access to Lucror’s research and analytics platform, please visit
- Johnny Yum
Strategy - Alpha Picks: First Month Of Underperformance In 2024
Our portfolio underperformed for the first time in 2024, delivering a 5.7% decline in May 24 compared with the JCI’s -3.6% return. Recent winners such as ACES and JSMR suffered the largest magnitude of decline, but we view this as an opportunity to add positions as their fundamentals are still positive. We add EXCL for its synergies with FREN and drop AKRA as its land sales could be delayed until 2H24. Our picks are EXCL, BSDE, TLKM, ACES, BBTN, CMRY, SIDO and JSMR.
- Lynn Song
- Min Joo Kang
- Nicky Mapa
- Rob Carnell
- Ceilica Su Rui
- Jo Yee Ng
- Johnny Yum
- Jonathan Koh
- Shirley Wang Xueyi
- Singapore Research Team
- Stella Guo Yuting
- Tham Mun Hon
Regional Morning Meeting Notes: Monday, June 03, 2024
GREATER CHINA Economics PMI May 24 PMI back to contraction. Sector Macau Gaming May 24 GGR up 9% mom. INDONESIA Strategy Alpha Picks: First Month Of Underperformance In 2024 Our picks are EXCL, BSDE, TLKM, ACES, BBTN, CMRY, SIDO, and JSMR. SINGAPORE Strategy Alpha Picks: Strong performance. Add CENT, CVL, SIA...
544 CSE GLOBAL LTD.
V03 VENTURE CORPORATION LIMITED
U96 SEMBCORP INDUSTRIES LTD.
JSMR PT JASA MARGA (PERSERO) TBK CLASS B
00027 GALAXY ENTERTAINMENT GROUP LIMITED
Z74 SINGAPORE TELECOMMUNICATIONS LIMITED
O39 OVERSEA-CHINESE BANKING CORPORATION LIMITED
BSDE PT BUMI SERPONG DAMAI TBK
599A SANDS CHINA LTD.
ACES PT ACE HARDWARE INDONESIA TBK
CENT CENTRAL GARDEN & PET COMPANY
PTI TELEKOMUNIKASI INDONESIA TBK PT (ADR)
FEHT FAR EAST HOSPITALITY TRUST
SIE SIA ENGINEERING CO LTD
SIDO INDUSTRI JAMU DAN FARMASI SI
TXG 10X GENOMICS INC CLASS A
FRKN FRENCKEN GROUP LTD
MPM MARCO POLO MARINE LTD
CVL CIVMEC
BBTN BANK TABUNGAN NEGARA PERSERO TBK PT
EXCL XL AXIATA TBK PT
MPACT MAPLETREE PAN ASIA COMMERCIAL TRUST
CMRY PT CISARUA MOUNTAIN DAIRY TBK
Z29 029 GROUP SE
- Johnny Yum
- Maskun Ramli
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in ...
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapyUnder the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply...
Mesoblast Corporate Presentation at Investor Conference
Mesoblast Corporate Presentation at Investor Conference NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Application (BLA) resubmission with the United States Food and Drug Administration (FDA) for its lead product candidate Ryoncil®(remestemcel-L) in the treatment of steroid-refractory acute graft versus host disease, with potential approval in the second ha...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.